We see you are located in China.
Do you want to switch to our Chinese website?

How AstraZeneca built smarter, constraint-based planning with OMP

See how a global biopharma leader replaced excess inventory with real visibility, and is now scaling with AI

Case study

Like many global biopharmaceutical companies, AstraZeneca leaned on significant inventory to protect service levels. It worked, but it came at a cost: rising working capital and limited visibility into what was really driving supply decisions.

Partnering with OMP, AstraZeneca rethought its approach, moving to constraint-based planning built around how planners actually work. The result: faster, more confident decisions, less reliance on inventory as a safety net, and a strong co-innovation partnership.

Now, AstraZeneca and OMP are pushing further, extending the planning solution with AI-enabled decision support to free planners to focus on the decisions that matter most.

 

What you'll learn in this case study:

  • Why AstraZeneca moved away from excess inventory, and what replaced it
  • How a hands-on partnership with OMP shaped a smoother path to adoption
  • What's next as AstraZeneca scales toward AI-enabled planning
How AstraZeneca built smarter, constraint-based planning with OMP

"With a constraint-based plan, we have visibility into capacity. We understand the materials available to manufacture the product, and we have greater transparency to assess customer needs and meet expected service levels."


Mark Trainor, Senior Director of Global Planning, Transformation and Technology, AstraZeneca

Case study